Radiation-induced damage in the upper gastrointestinal tract: clinical presentation, diagnostic tests and treatment options.
Damage
Gastritis
Gastrointestinal
Gastrointestinal bleeding
Oesophagitis
Radiation
Ulcers
Journal
Best practice & research. Clinical gastroenterology
ISSN: 1532-1916
Titre abrégé: Best Pract Res Clin Gastroenterol
Pays: Netherlands
ID NLM: 101120605
Informations de publication
Date de publication:
Historique:
received:
29
07
2020
revised:
05
11
2020
accepted:
09
11
2020
entrez:
15
12
2020
pubmed:
16
12
2020
medline:
28
1
2021
Statut:
ppublish
Résumé
Radiation-induced damage of the upper gastrointestinal (GI) tract results from radiation of GI tumors or structures adjacent to the GI tract. Radiation-induced damages of the upper GI tract may be acute or delayed, and ranges from lack of appetite, mucosal inflammation (i.e. esophagitis, gastritis, duodenitis) to ulcers, which may be complicated by perforation, penetration, bleeding and stenosis. Radiation-related factors as well as individual patient predisposing factors may increase susceptibility to post-radiation damage. High quality evidence for the treatment of radiation-induced GI damage is scarce and the management is often extrapolated from studies on GI lesions of different etiology. Treatment depends on severity and localization of the radiation-induced damage, and ranges from supportive and dietary measures to endoscopic interventions or surgery. Modern radiation techniques may decrease the incidence and severity of the radiation-induced upper gastrointestinal disease.
Identifiants
pubmed: 33317797
pii: S1521-6918(20)30046-9
doi: 10.1016/j.bpg.2020.101711
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101711Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest M.V., honoraria from Nordic Pharma, Merck Serono, Bayer Vital, Lilly and Sirtex and advisory role for Ipsen, Lilly, Nordic Pharma, BMS, MSD, Eisai, and Amgen. A.A., M.P., D.J., T.B., and J.W. declare no conflict of interest.